<DOC>
	<DOCNO>NCT01525550</DOCNO>
	<brief_summary>The purpose study confirm safety efficacy sunitinib subject unresectable pancreatic neuroendocrine tumor .</brief_summary>
	<brief_title>A Study Of The Efficacy And Safety Of Sunitinib In Patients With Advanced Well-Differentiated Pancreatic Neuroendocrine Tumors</brief_title>
	<detailed_description>This study conduct meet regulatory post-marketing commitment .</detailed_description>
	<mesh_term>Neuroendocrine Tumors</mesh_term>
	<mesh_term>Carcinoid Tumor</mesh_term>
	<mesh_term>Adenoma , Islet Cell</mesh_term>
	<mesh_term>Sunitinib</mesh_term>
	<criteria>Histologically cytologically proven diagnosis welldifferentiated pancreatic neuroendocrine tumor ( accord World Health Organization [ WHO 2000 ] classification ) . Disease progression within 12 month prior study enrollment . Disease amenable surgery , radiation , combine modality therapy curative intent . Patients poorly differentiate pancreatic neuroendocrine tumor ( accord WHO 2000 classification ) . Prior treatment tyrosine kinase inhibitor , anti vascular endothelial growth factor ( VEGF ) angiogenesis inhibitor , non VEGF target angiogenesis inhibitor , mammalian target rapamycin ( mTOR ) inhibitor .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>neuroendocrine tumor</keyword>
	<keyword>adenoma islet cell</keyword>
	<keyword>carcinoma islet cell</keyword>
	<keyword>pancreatic neoplasm</keyword>
	<keyword>angiogenesis inhibitor</keyword>
	<keyword>sunitinib</keyword>
	<keyword>neoplasm</keyword>
	<keyword>carcinoma</keyword>
	<keyword>adenoma</keyword>
</DOC>